Association of Serum CTRP4 Levels with Vascular Endothelial Function in Patients with Type 2 Diabetes Mellitus: CTRP4 Ameliorating Inflammation, Proliferation and Migration in Human Umbilical Vein Endothelial Cells

Overview

Journal Acta Diabetol

Specialty Endocrinology

Date 2024 Jan 29

PMID 38286878

Authors

Jie Gao

Mai Re YanMu Rouzi

Huihui Zhang

Xinghua Cai

Bilin Xu

Jun Lu

Tao Lei

Affiliations

Soon will be listed here.

Abstract

Objective: We investigated the correlation between serum C1q/TNF-related protein 4 (CTRP4) level and flow-mediated dilation (FMD) in patients with type 2 diabetes mellitus (T2DM), and evaluated the biological effects of CTRP4 on human umbilical vein endothelial cells (HUVECs).

Methods: A group of 165 patients diagnosed with T2DM were included in this study. Endothelial function was measured with the examination of brachial artery FMD. ELISA kit was used to measure the levels of CTRP4 in serum. HUVECs were stimulated with recombinant CTRP4 protein to assess its biological functions.

Results: The levels of CTRP4 showed a significant variation among three groups based on FMD tertiles (p = 0.001). What's more, FMD had a significant difference among three CTRP4 tertile groups (p < 0.05) and was negatively related to serum CTRP4 levels (r = -0.270, p < 0.001). In T2DM patients, logistic regression analysis demonstrated that CTRP4 was the primary influence factor of low FMD (p < 0.01). In receiver operating characteristic curve analysis, the area under the curve of CTRP4 for predicting low FMD was 0.66 (95%CI 0.58-0.75). When stimulated HUVECs with recombinant CTRP4 protein, we found that CTRP4 could concentration-dependently ameliorate proliferation and migration of HUVECs in wounding healing and transwell assay. This protein could also decrease the expression of IL-6 and TNF-α and promote the release of NO in HUVEC supernatants, with suppression of NF-κB and STAT3 phosphorylation.

Conclusions: Serum CTRP4 concentrations were negatively associated with FMD. CTRP4 alleviated proliferation, migration and inflammation in HUVECs through the suppression of NF-κB and STAT3 signaling pathways.

Citing Articles

The Immune-Centric Revolution Translated into Clinical Application: Peripheral Blood Mononuclear Cell (PBMNC) Therapy in Diabetic Patients with No-Option Critical Limb-Threatening Ischemia (NO-CLTI)-Rationale and Meta-Analysis of Observational....

Rehak L, Giurato L, Monami M, Meloni M, Scatena A, Panunzi A J Clin Med. 2024; 13(23).

PMID: 39685690 PMC: 11642624. DOI: 10.3390/jcm13237230.

References

Cao L, Deng J, Chen W, He M, Zhao N, Huang H . CTRP4/interleukin-6 receptor signaling ameliorates autoimmune encephalomyelitis by suppressing Th17 cell differentiation. J Clin Invest. 2023; 134(4). PMC: 10866667. DOI: 10.1172/JCI168384. View

Wang J, Hang T, Cheng X, Li D, Zhang Q, Wang L . Associations of C1q/TNF-Related Protein-9 Levels in Serum and Epicardial Adipose Tissue with Coronary Atherosclerosis in Humans. Biomed Res Int. 2015; 2015:971683. PMC: 4589613. DOI: 10.1155/2015/971683. View

Huang N, Buzkova P, Matthan N, Djousse L, Kizer J, Mukamal K . Serum Non-Esterified Fatty Acids, Carotid Artery Intima-Media Thickness and Flow-Mediated Dilation in Older Adults: The Cardiovascular Health Study (CHS). Nutrients. 2021; 13(9). PMC: 8465602. DOI: 10.3390/nu13093052. View

Shahin Y, Alam Khan J, Samuel N, Chetter I . Angiotensin converting enzyme inhibitors effect on endothelial dysfunction: a meta-analysis of randomised controlled trials. Atherosclerosis. 2011; 216(1):7-16. DOI: 10.1016/j.atherosclerosis.2011.02.044. View

Kishore U, Gaboriaud C, Waters P, Shrive A, Greenhough T, Reid K . C1q and tumor necrosis factor superfamily: modularity and versatility. Trends Immunol. 2004; 25(10):551-61. DOI: 10.1016/j.it.2004.08.006. View

Lundman P, Eriksson M, Stuhlinger M, Cooke J, Hamsten A, Tornvall P . Mild-to-moderate hypertriglyceridemia in young men is associated with endothelial dysfunction and increased plasma concentrations of asymmetric dimethylarginine. J Am Coll Cardiol. 2001; 38(1):111-6. DOI: 10.1016/s0735-1097(01)01318-3. View

Cao L, Tan W, Chen W, Huang H, He M, Li Q . CTRP4 acts as an anti-inflammatory factor in macrophages and protects against endotoxic shock. Eur J Immunol. 2020; 51(2):380-392. DOI: 10.1002/eji.202048617. View

Moradi N, Fadaei R, Emamgholipour S, Kazemian E, Panahi G, Vahedi S . Association of circulating CTRP9 with soluble adhesion molecules and inflammatory markers in patients with type 2 diabetes mellitus and coronary artery disease. PLoS One. 2018; 13(1):e0192159. PMC: 5790264. DOI: 10.1371/journal.pone.0192159. View

Ras R, Streppel M, Draijer R, Zock P . Flow-mediated dilation and cardiovascular risk prediction: a systematic review with meta-analysis. Int J Cardiol. 2012; 168(1):344-51. DOI: 10.1016/j.ijcard.2012.09.047. View

10.

Williams S, Cusco J, Roddy M, Johnstone M, Creager M . Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. J Am Coll Cardiol. 1996; 27(3):567-74. DOI: 10.1016/0735-1097(95)00522-6. View

11.

Gao J, Lu J, Qiu J, Sun D, Xu B, Wang Z . C1q tumor necrosis factor-related protein 4 is associated with coronary artery disease in patients with type 2 diabetes. J Diabetes Investig. 2022; 13(10):1723-1731. PMC: 9533036. DOI: 10.1111/jdi.13842. View

12.

Peterson J, Aja S, Wei Z, Wong G . CTRP1 protein enhances fatty acid oxidation via AMP-activated protein kinase (AMPK) activation and acetyl-CoA carboxylase (ACC) inhibition. J Biol Chem. 2011; 287(2):1576-87. PMC: 3256898. DOI: 10.1074/jbc.M111.278333. View

13.

Henry R, Ferreira I, Kostense P, Dekker J, Nijpels G, Heine R . Type 2 diabetes is associated with impaired endothelium-dependent, flow-mediated dilation, but impaired glucose metabolism is not; The Hoorn Study. Atherosclerosis. 2004; 174(1):49-56. DOI: 10.1016/j.atherosclerosis.2004.01.002. View

14.

Xu S, Ilyas I, Little P, Li H, Kamato D, Zheng X . Endothelial Dysfunction in Atherosclerotic Cardiovascular Diseases and Beyond: From Mechanism to Pharmacotherapies. Pharmacol Rev. 2021; 73(3):924-967. DOI: 10.1124/pharmrev.120.000096. View

15.

Zheng Y, Ley S, Hu F . Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2017; 14(2):88-98. DOI: 10.1038/nrendo.2017.151. View

16.

Radenkovic M, Stojanovic M, Prostran M . Calcium Channel Blockers in Restoration of Endothelial Function: Systematic Review and Meta-Analysis of Randomized Controlled Trials. Curr Med Chem. 2018; 26(29):5579-5595. DOI: 10.2174/0929867325666180713144806. View

17.

Schaffler A, Buechler C . CTRP family: linking immunity to metabolism. Trends Endocrinol Metab. 2012; 23(4):194-204. DOI: 10.1016/j.tem.2011.12.003. View

18.

Polovina M, Potpara T . Endothelial dysfunction in metabolic and vascular disorders. Postgrad Med. 2014; 126(2):38-53. DOI: 10.3810/pgm.2014.03.2739. View

19.

Li B, Zhang Q, Zhang H, Wang C, Xiu R . Effects of nebivolol versus other antihypertensive drugs on the endothelial dysfunction in patients with essential hypertension. Biosci Rep. 2020; 40(5). PMC: 7201558. DOI: 10.1042/BSR20200436. View

20.

. 2. Classification and Diagnosis of Diabetes: . Diabetes Care. 2020; 44(Suppl 1):S15-S33. DOI: 10.2337/dc21-S002. View